← Back to Home

Seven Patients with Previously Unresectable Pancreatic Cancer Undergo Surgery After Light-Activated Therapy

A phase 1 trial enabled some patients with locally advanced pancreatic cancer to proceed to surgery, with no cancer cells found at the resection margins in four patients. This is an early signal worth following, but the small, uncontrolled study cannot yet establish whether the therapy extends survival.

By SURL BioNews

For patients with locally advanced pancreatic cancer, the relationship between the tumor and surrounding blood vessels may determine whether surgery is feasible. Preliminary results have now emerged for an experimental light-activated therapy: of 12 patients whose tumors were initially deemed unresectable, seven have undergone resection after treatment. However, key evidence is still needed to establish whether renewed access to surgery translates into better long-term outcomes.

ImPact Biotech announced on October 23 that these patients received padeliporfin vascular-targeted photodynamic therapy (VTP). In addition to the seven who have undergone surgery, two others are scheduled for surgery; these two groups cannot be combined and counted as completed resections. Among the seven patients who underwent surgery, four had pathologically confirmed R0 resections, meaning that no tumor cells were seen under a microscope at the margins of the removed tissue. This does not mean that no cancer remains in the body or that it will not recur.

The therapy combines a drug with a fiber-optic device. According to trial information published by the University of California, Irvine and the U.S. National Cancer Institute, patients first receive intravenous padeliporfin at 4 milligrams per kilogram of body weight. An optical fiber placed inside the target artery then delivers light at a wavelength of 753 nanometers for 10 minutes to activate the drug locally. The study aims to use this approach to treat lesions at the interface between the tumor and blood vessels and explore whether it can increase the likelihood of subsequent resection.

This study does not cover all patients with pancreatic cancer. The trial, numbered NCT05919238, enrolls patients with stage III locally advanced unresectable pancreatic ductal adenocarcinoma located in the pancreatic head or uncinate process and excludes those with distant metastases. The criteria listed by the National Cancer Institute also allow patients who have previously received chemotherapy or immunotherapy, or undergone an attempted resection, but exclude those who have received radiation therapy to the pancreas. These eligibility criteria must therefore be considered when assessing which patients the results may apply to.

The study has a multicenter, nonrandomized, open-label design and plans to enroll 30 patients. Part A uses a “3+3” approach to progressively test three light doses, followed by an expanded evaluation at the selected dose in Part B. The company's announcement concerns early observations from 12 patients in Part A. Information updated by UC Irvine on October 5 lists an estimated study completion date of December 2027 and does not yet include the newly announced surgical results. The pages from the two public institutions can be used to verify the trial design, while the surgical outcomes currently come from the company's announcement.

The main limitations in interpreting this signal are the lack of a control group and the possibility that patients had received other treatments, making it difficult to attribute the results to VTP alone. The announcement also did not provide complete individual treatment histories, postoperative follow-up, recurrence data, or survival data. The company said that no major safety concerns had emerged to date, but it did not list detailed adverse event data, leaving insufficient information for a full assessment of the risks.

The next expanded study needs to address more than how many patients can proceed to surgery. It must also assess whether resection can provide durable disease control and the safety of combining the treatment with surgery. The four R0 resections provide a reason to continue studying this approach; more complete and comparative evidence is still needed before it can become a clinical option.

References

  1. ImPact Biotech via GlobeNewswire
  2. University of California, Irvine
  3. National Cancer Institute